Skip to main content
SpringerLink
Log in

Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Anticoagulation management in patients with cirrhosis presents several challenges as a result of alterations in hemostasis. Historically vitamin k antagonists and low molecular weight heparins have been the agents of choice in this patient population. Direct oral anticoagulants (DOACs) may provide an alternative to traditional anticoagulant therapy. To evaluate the rate of major bleeding among patients receiving DOACs or warfarin with cirrhosis. A retrospective, observational, cohort study of adult patients admitted between January 2012 and July 2018 with diagnosis of cirrhosis receiving anticoagulation with DOAC or warfarin therapy was performed. Patients were stratified based on the receipt of a DOAC or warfarin. The primary endpoint was incidence of major bleeding at 90 days. Secondary endpoints included stroke or embolic event at 90 days as well as rehospitalization and mortality at 1 year. One hundred sixty-seven patients were included for analysis; of which 110 received warfarin and 57 received a DOAC. The most commonly used DOAC was apixaban (52.6%) followed by rivaroxaban (45.6%) and dabigratran (1.8%). The incidence of major bleeding was similar between warfarin and DOAC groups (9.1% vs. 5.2% p = 0.381). No difference in the rate of stroke or recurrent embolic event at 90 days was identified between the two groups (0% vs. 1.58% p = 0.341; 1.8% vs. 1.8% p = 0.731). In conclusion DOACs appear to be a safe alternative to warfarin in patients with mild to moderate cirrhosis. Further studies are warranted to confirm these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AF:

Atrial fibrillation

CVA:

Cerebrovascular accident

CTP:

Child–Turcotte–Pugh

DOAC:

Direct oral anticoagulant

INR:

International normalized ratio

MELD:

Model for end-stage liver disease

References

  1. Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP (2018) Oral anticoagulation in patients with liver disease. J Am Coll Cardiol. 71(19):2162–2175

    Article  CAS  Google Scholar 

  2. Delgado MG, Seijo S, Yepes I et al (2012) Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 10:776–783

    Article  Google Scholar 

  3. Kuo L, Chao TF, Liu CJ et al (2017) Liver cirrhosis in patients with atrial fibrillation: would oral anticoagulation have a net clinical benefit for stroke prevention? J Am Heart Assoc 6:e005307

    Article  Google Scholar 

  4. Hu J, Xu Y, He Z et al (2018) Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget. 9:2752–2760

    Article  Google Scholar 

  5. Sogaard KK, Horvath-Puho E, Gronbaek H, Jepsen P, Vilstrup H, Sorensen HT (2009) Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case control study. Am J Gastroenterol. 104:96–101

    Article  Google Scholar 

  6. Amitrano L, Guardascione MA, Menchise A et al (2010) Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 44:448–451

    CAS  PubMed  Google Scholar 

  7. Tripodi A, Salerno F, Chantarangkul V et al (2005) Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 41:553–558

    Article  CAS  Google Scholar 

  8. Intagliata NM, Henry ZH, Maitland H et al (2016) Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci 61(6):1717–1721

    Article  Google Scholar 

  9. Hum J, Shatzel JJ, Jou JH, Deloughery TG (2017) The efficacy and safety of direct oral anticoagulants vs. traditional anticoagulants in cirrhosis. Eur J Haematol 98(4):393–397

    Article  CAS  Google Scholar 

  10. Goriacko P, Veltri KT (2018) Safety of direct oral anticoagulants vs. warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol 100(5):488–493

    Article  CAS  Google Scholar 

  11. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Torres-Ortiz A, O’Corragain OA, Watthanasuntorn K et al (2019) Efficacy and safety of anticoagulation for atrial fibrillation in patients with cirrhosis: a systematic review and meta-analysis. Dig Liver Dis 51:489–495

    Article  Google Scholar 

  12. Schulman S, Kearon C (2005) Subcommittee on control of anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of anti-hemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694

    Article  CAS  Google Scholar 

  13. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381

    Article  Google Scholar 

  14. Tripodi A, Mannucci PM (2011) The coagulopathy of chronic liver disease. N Engl J Med 365(2):147–156

    Article  CAS  Google Scholar 

  15. US FDA Edoxaban. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf. Accessed 1 Aug 2018

  16. US FDA Rivaroxaban. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf. Accessed 1 Aug 2018

  17. US FDA. Dabigatran. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s027lbl.pdf. Accessed 1 Aug 2018

  18. US FDA Betrixaban. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf. Accessed 1 Aug 2018

  19. Kunk PR, Collins H, Palkimas S et al (2016) Direct oral anticoagulants in patients with cirrhosis appear safe and effective. Blood 128:3827

    Article  Google Scholar 

Download references

Funding

No funding was utilized for this study.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Wake Forest Baptist Health, 1 Medical Center Boulevard, Winston Salem, NC, 27157, USA

    Kyle A. Davis

  2. Department of Internal Medicine, Wake Forest Baptist Health, 1 Medical Center Boulevard, Winston Salem, NC, 27157, USA

    Joel Joseph

  3. Department of Pharmacy, Wake Forest Baptist Health, School of Pharmacy, Wingate University, 515 N. Main St, Wingate, NC, 28174, USA

    Sarah A. Nisly

Authors
  1. Kyle A. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joel Joseph
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sarah A. Nisly
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. SN and KD contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. JJ contributed to the data collection and analysis as well as manuscript preparation.

Corresponding author

Correspondence to Kyle A. Davis.

Ethics declarations

Conflict of interest

All authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Davis, K.A., Joseph, J. & Nisly, S.A. Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes. J Thromb Thrombolysis 50, 457–461 (2020). https://doi.org/10.1007/s11239-019-02035-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-019-02035-0

Keywords

Search

Navigation